MiRXES invests S$8M in 4.0 IVD manufacturing facility

MiRXES, a Singapore-headquartered biotechnology company, and A*STAR spinoff, focused on saving and improving lives with miRNA-powered cancer early detection tests, has announced the opening of the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site in Southeast Asia at 15,000 square feet. This brand new I4.0 manufacturing facility will greatly advance the IVD productisation and manufacturing capabilities as MiRXES accelerates the development and commercialisation of maturing pipeline of multi cancer early detection tests, pulmonary and cardiovascular disease tests, as well as life sciences and infectious disease portfolio. This first-of-its kind facility in Southeast Asia will equip MiRXES to address the next big challenge in healthcare – cancer, and stay prepared should we need to combat another epidemic. The setup of this Industry 4.0-compliant IT infrastructure was supported by A*STAR’s ARTC.